Nuzenio

Denali Therapeutics

Denali Therapeutics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 24 latest news signals 10 publisher sources 100/100 entity strength

Latest news

Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Analysts - MarketBeatMarketBeat · Sat, 08 Aug 2026 06:47:15 GMTDenali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen - MarketBeatMarketBeat · Sat, 08 Aug 2026 05:48:58 GMTDenali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue - simplywall.stsimplywall.st · Sat, 08 Aug 2026 03:05:24 GMTDNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - TradingViewTradingView · Fri, 07 Aug 2026 18:31:00 GMTDenali Therapeutics: Blood-Brain Barrier Platform Shows More Than 1,000x Greater Brain Exposure In Primates As AVLAYAH Launch Accelerates - Pulse 2.0Pulse 2.0 · Fri, 07 Aug 2026 15:50:29 GMTUBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 14:33:34 GMTDenali Therapeutics Inc. Stock 12‑Month Price Target Raised to $35.44, Implies 43% Upside - TradingViewTradingView · Fri, 07 Aug 2026 14:20:14 GMTDenali Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 12:30:00 GMT

Timeline

Sat, 08 Aug 2026 06:47:15 GMTDenali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Sat, 08 Aug 2026 05:48:58 GMTDenali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Sat, 08 Aug 2026 03:05:24 GMTDenali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue - simplywall.st
Fri, 07 Aug 2026 18:31:00 GMTDNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - TradingView
Fri, 07 Aug 2026 15:50:29 GMTDenali Therapeutics: Blood-Brain Barrier Platform Shows More Than 1,000x Greater Brain Exposure In Primates As AVLAYAH Launch Accelerates - Pulse 2.0
Fri, 07 Aug 2026 14:33:34 GMTUBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating - marketscreener.com

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Denali Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

10 distinct publisher/source names are currently connected to this entity page.